Belgian Construction Stock News

Why Azelis Group is on investors’ radar Azelis Group (ENXTBR:AZE) has caught investor attention after a recent share price move, with the stock showing a mix of short term gains and longer term weakness that raises fresh questions about its current valuation. See our latest analysis for Azelis Group. The recent rally, including a 23.88% 30 day share price return and 5.37% 7 day share price return to €9.415, comes against a much weaker backdrop, with a 36% 1 year total shareholder return...

BlackRock, Inc. disclosed that its direct voting rights in Umicore (ENXTBR:UMI) moved above the 5% threshold, then later fell back below 5%, within a short period. The changes were reported through regulatory filings, highlighting shifts in a major institutional investor's position in the company. Crossing the 5% level triggers mandatory disclosure rules, which can draw market attention to institutional ownership in Umicore. Umicore operates in materials technology and recycling, with...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Norse Wind vessel puts DEME Group (ENXTBR:DEME) in focus DEME Group (ENXTBR:DEME) has drawn fresh investor attention after christening the Norse Wind, a new offshore wind installation vessel equipped with a 3,200-tonne crane and a hybrid power system. The ship is built to install larger next generation turbines and operate in harsher offshore conditions. Its hybrid setup targets more than 70% emission reductions. Norse Wind already carries long term contracts for major European offshore wind...

Why Solvay (ENXTBR:SOLB) Is On Investors’ Radar Today Solvay (ENXTBR:SOLB) has caught investor attention after recent share price moves, with the stock closing at €27.18 and showing mixed return patterns over the past week, month and past 3 months. See our latest analysis for Solvay. Recent trading has been steady rather than dramatic, with a 6.8% 1 month share price return and a slightly negative year to date move, while the 5 year total shareholder return of 58.6% reflects a stronger longer...

As European markets experience a boost in sentiment due to hopes of a shorter Middle East conflict, indices like the STOXX Europe 600 and Germany's DAX have shown notable gains. In this environment, identifying stocks that may be trading below their estimated value can offer opportunities for investors looking to capitalize on potential market inefficiencies.

Onward Medical (ENXTBR:ONWD) has reported its FY 2025 first half with revenue of €1.2 million, a basic EPS loss of €0.47, and net income loss of €21.2 million, setting a clear tone for another year focused on growth over profitability. The company has seen revenue move from €0.2 million in the first half of 2024 to €1.5 million in the second half of 2024 and €1.2 million in the first half of 2025. Basic EPS has shifted between losses of €0.53, €0.32, and €0.47 over the same periods,...

Syensqo (ENXTBR:SYENS) has wrapped up FY 2025 with fourth quarter revenue of €1,384 million and basic EPS of a €1.61 loss, while the trailing twelve months show revenue of €5,969 million and basic EPS of a €0.85 loss. Over recent quarters, revenue has moved from €1,662 million in Q4 2024 to €1,678 million in Q1 2025, €1,639 million in Q2 2025, €1,558 million in Q3 2025, and €1,384 million in Q4 2025, with EPS swinging between a €1.28 loss and a €0.49 gain before landing at a €1.61 loss this...

As European markets navigate the complexities of Middle East conflicts and energy price volatility, indices like the STOXX Europe 600 have shown modest gains, reflecting a cautious optimism amidst geopolitical uncertainties. In these fluctuating times, dividend stocks can offer investors a measure of stability and potential income, making them an appealing consideration for those looking to balance risk with consistent returns.

Syensqo share performance snapshot Syensqo (ENXTBR:SYENS) has attracted attention after a recent move that left the stock about 2% higher over the past month, yet showing a roughly 28% decline over the past 3 months. Over the past year, Syensqo’s total return is about 20% lower, while year to date performance shows a similar decline of around 29%. These moves provide context for assessing its current valuation. See our latest analysis for Syensqo. Syensqo’s share price, now at €49.48, has...

Syensqo has redeemed €500 million of senior bonds that were originally due in 2027. This move completes a wider debt refinancing step following the company’s recent spin off. The early redemption changes the company’s debt profile and may influence future interest costs. The bond redemption comes at a time when Syensqo (ENXTBR:SYENS) shares trade around €49.0. The stock has seen a 12.6% gain over the past week, while returns over the past month, year to date, and past year show declines of...

SCR-Sibelco N.V.'s ( EBR:094426466 ) healthy profit numbers didn't contain any surprises for investors. However the...

Sofina Société Anonyme (ENXTBR:SOF) opened FY 2025 with a weak first half, reporting a loss as basic EPS swung to €11.87 and total revenue came in at a loss of €358.9 million. This comes against a backdrop where the trailing twelve months still show positive EPS of €12.48 and revenue of €486.1 million. Over the past year, the company has seen total revenue move from €587.1 million in 2024 H1 to €844.98 million in 2024 H2 and EPS shift from €16.59 to €24.29 in the same periods, before the...

The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index declining by 3.79% amid heightened geopolitical tensions and soaring energy costs, prompting caution from the European Central Bank regarding inflation risks. In this environment of uncertainty, high-growth tech stocks in Europe are gaining attention for their potential to offer resilience and innovation-driven growth, making them an intriguing focus for investors seeking opportunities in a...

Today is shaping up negative for Banqup Group SA ( EBR:BANQ ) shareholders, with the analysts delivering a substantial...

SCR-Sibelco (ENXTBR:094426466) has put fresh numbers on the table for FY 2025, reporting first half revenue of €1.2b and net income of €78.1m, while trailing 12 month revenue is €2.3b against net income of €63.4m. Over the past year, revenue has moved from €1.1b in the first half of 2024 and €1.1b in the second half of 2024 to €1.2b in the first half of 2025. Net income shifted from €145.9m to a loss of €14.7m and then to €78.1m over the same periods. For investors, the key storyline is how...

Nyxoah (ENXTBR:NYXH) just wrapped up FY 2025 with Q4 revenue of €5.6 million and a basic EPS loss of €0.586, alongside trailing twelve month revenue of €10.0 million and a basic EPS loss of €2.364 on net income losses of €90.1 million. Over recent quarters the company has seen revenue move from €1.3 million in Q4 2024 to €5.6 million in Q4 2025, while quarterly basic EPS losses widened from €0.463 to €0.586 and trailing twelve month net income losses went from €59.2 million to €90.1 million...

What Elia Group’s latest earnings mean for shareholders Elia Group (ENXTBR:ELI) released full year 2025 results on 5 March, reporting sales of €4,442.2m and net income of €585.9m, figures that helped shape recent sentiment around the stock. See our latest analysis for Elia Group. Elia Group’s recent earnings update has arrived alongside firm share price momentum, with a 28.6% 90 day share price return and a 70.54% 1 year total shareholder return indicating that optimism has been building...

D'Ieteren Group (ENXTBR:DIE) has just posted its FY 2025 numbers with first half revenue of about €4.1b and basic EPS of €4.61, backed by trailing 12 month EPS of €8.40 that lines up with reported earnings growth of 17.3% over the past year. The company has seen revenue move from about €4.3b in the first half of 2024 and €3.9b in the second half of 2024 to €4.1b in the first half of 2025. Trailing 12 month net income, excluding extra items, sits at €445m, alongside earnings growth of roughly...

Proximus (ENXTBR:PROX) has just released its full year 2025 results, reporting €6,248 million in sales, €6,620 million in revenue, and net income of €398 million, with earnings per share of €1.23. See our latest analysis for Proximus. At a share price of €7.29, Proximus has had a mixed run, with a 9.05% decline in its 1 month share price return and a 4.29% gain over 3 months. Its 1 year total shareholder return of 16.63% contrasts with a 39.98% total shareholder return decline over five...

Cmb.Tech (ENXTBR:CMBT) has drawn investor attention after reporting full year 2025 results, declaring an interim dividend of US$0.16 per share and announcing a Management Board change involving Chief Strategy Officer Benoit Timmermans. See our latest analysis for Cmb.Tech. The share price has pulled back over the past week with a 7 day share price return of a 6.27% decline. However, the 90 day share price return of 37.34% and 1 year total shareholder return of 43.99% point to momentum that...

Syensqo SA has recently reported weaker fourth-quarter and full-year 2025 results, announced an annual dividend of €1.1340 per share for payment on 18 May 2026, redeemed €500,000,000 of 2.750% fixed-rate bonds early, and confirmed several Board changes including appointing Heike van de Kerkhof as independent Chair. These moves combine pressure on profitability with balance sheet reshaping and refreshed governance, giving investors a complex mix of cost, capital allocation and oversight...

Shurgard Self Storage (ENXTBR:SHUR) caught investor attention after releasing its 2025 results, reporting revenue of €450.85 million and net income of €597.76 million, along with fresh 2026 guidance for 6% to 8% all store revenue growth. See our latest analysis for Shurgard Self Storage. The latest guidance and 2025 results came after a weak patch for the shares, with a 30-day share price return showing a 10.62% decline and a 1-year total shareholder return showing a 9.73% decline. The recent...

Argenx (ENXTBR:ARGX) reported positive topline Phase 3 ADAPT OCULUS results for VYVGART in adults with ocular myasthenia gravis. The study met its primary endpoint with statistically significant efficacy in this patient group, which currently has limited treatment options. The data are intended to support regulatory submissions that could extend the existing VYVGART label to include ocular myasthenia gravis. Argenx is pairing these results with a broader push to expand VYVGART indications...